Sunday, 15 November 2026European Markets
Source trace. Via News points to the documents behind its reporting and shows what we drew from each, so you can check any claim. How we source
News articleYahoo Finance· September 30, 2026

Cboe and Robinhood Announce Planned Launch of New KPI Contracts, Further Expanding Prediction Market Offerings

View original at finance.yahoo.com
Cboe and Robinhood Announce Planned Launch of New KPI Contracts, Further Expanding Prediction Market Offerings Products tied to 23 companies to roll out in October, subject to regulatory approval CHICAGO, Sept…
Opening lines of the source · Yahoo Finance · short snapshot: read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • KPI contracts are designed to provide exposure to key corporate metrics and a granular way to trade individual components tracked each quarter; Cboe believes they will appeal to a broad range of participants from systematic traders to retail investors.

    60% confidence
  • Cboe's framework differentiates its products from similar event-based contracts on designated contract markets and reflects its view that these securities products should trade within U.S. securities market transparency, oversight and investor protections, including federal preemption of state securities registration requirements.

    60% confidence
  • Planned launch comes amid growing investor demand for intuitive, event-driven products directly based on the companies investors follow.

    60% confidence
  • Earnings contracts give retail investors another tool to inform their strategies and a more precise way to trade on anticipated company KPIs.

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Cluster: Late-Stage Data and PDUFA Dates Converge
Early-to-mid November 2026 is a dense run of clinical readouts and Q3 earnings at AHA, AASLD, ACR and ASH. Mid-cap biotechs (Vir, Mineralys, Arrowhead, Oryzon, Novartis, J&J) are reporting data that feeds into regulatory decisions. The next ones are the ivonescimab BLA (Nov 14) and the lorundrostat PDUFA (Dec 22), followed by ECLIPSE 2/3 and Maritime-1 readouts in Q1 2027. The list also includes an unrelated delisting track (EGM Nov 19, application Jan 25, 2027), and the facts have no AI or fintech content.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Sources reconciled: no open conflicts right now.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,959
facts traced to their source, and we flag the ones that don't hold up.
101 entities tracked4,959 facts checked against source5,585 source documents archived
Query this data → isubstrate.com